Your session is about to expire
What is Gengraf
CyclosporineThe Generic name of this drug
Treatment SummaryCyclosporine is a medication used to prevent organ transplant rejection and treat inflammatory and autoimmune conditions. It is derived from a fungus called Beauveria nivea and was first manufactured by Sandoz in 1983. It is now available in various brands, such as Novartis, which was formerly known as Sandoz.
Sandimmuneis the brand name
Gengraf Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Sandimmune
Cyclosporine
1983
68
Approved as Treatment by the FDA
Cyclosporine, also known as Sandimmune, is approved by the FDA for 20 uses which include Patients who do not adequately respond to methotrexate alone and Not responsive to other therapy .Patients who do not adequately respond to methotrexate alone
Used to treat Patients who do not adequately respond to methotrexate alone in combination with Methotrexate
Not responsive to other therapy
Helps manage Not responsive to other therapy
Liver
Prophylaxis against graft versus host disease
Bone Marrow Transplantation
Heymann Nephritis
Helps manage Glomerulonephritis, Membranous
Transplantation
Chronic Graft Versus Host Disease
Therapeutic immunosuppression
Prophylaxis against stem cell transplant rejection
Prophylaxis against heart transplant rejection
severe, recalcitrant Plaque psoriasis
Helps manage severe, recalcitrant Plaque psoriasis
Rheumatoid Arthritis
Helps manage severe, active Rheumatoid arthritis
Nephrotic Syndrome
Helps manage Nephrotic Syndrome
Bone Marrow
Glomerulosclerosis, Focal Segmental
Helps manage Focal Segmental Glomerulosclerosis (FSGS)
Glomerulosclerosis
Helps manage Glomerulosclerosis
Kidney Transplantation
Nephrotic Syndrome
Helps manage Steroid Resistant Nephrotic Syndrome
Nephrotic Syndrome
Helps manage Steroid Dependent Nephrotic Syndrome
Effectiveness
How Gengraf Affects PatientsCyclosporine is a drug used to suppress the activity of the immune system, helping to prolong the success of organ and bone marrow transplants. It also helps to prevent and control serious immune-related reactions, such as allograft rejection, graft versus host disease, and autoimmune disease. However, it can cause certain side effects, such as excessive hair growth, gum enlargement, increased cholesterol levels, and in some cases, kidney damage.
How Gengraf works in the bodyCyclosporine is a drug that stops inflammation by blocking the activation of T cells. It does this by binding to a receptor inside cells and forming a complex. This complex then prevents calcineurin from activating a certain factor, called NF-AT, which triggers the production of inflammatory chemicals like cytokines. By stopping this process, cyclosporine can reduce inflammation and stop T cell activation or growth. It also lowers levels of other substances associated with T cell function and thymocyte development.
When to interrupt dosage
The suggested dosage of Gengraf is contingent upon the diagnosed condition, such as Interstitial Cystitis, Focal Segmental Glomerulosclerosis (FSGS) and Excessive tearing. The measure of dosage is dependent on the mode of administration (e.g. Liquid - Intravenous or Ophthalmic; Topical) listed in the table below.Condition
Dosage
Administration
Ulcerative Colitis
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Nephrotic Syndrome
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Cystitis, Interstitial
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Bone Marrow
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Conjunctivitis, Allergic
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Rosacea
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Disease
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Nephrotic Syndrome
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Juvenile arthritis
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Bone Marrow Transplantation
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Prophylaxis against stem cell transplant rejection
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Dry Eye Syndromes
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Therapeutic immunosuppression
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Not responsive to other therapy
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Transplantation
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Chronic Graft Versus Host Disease
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Organ Transplantation
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Patients who do not adequately respond to methotrexate alone
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Heymann Nephritis
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Nephrotic Syndrome
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Warnings
Gengraf has six contraindications. It should not be taken simultaneously with any of the conditions noted in the following table.Gengraf ContraindicationsCondition
Risk Level
Notes
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Psoriasis
Do Not Combine
Abnormal Renal Function
Do Not Combine
Hypertensive disease
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Cyclosporine may interact with Pulse Frequency
Common Gengraf Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The serum concentration of Abemaciclib can be increased when it is combined with Cyclosporine.
Acalabrutinib
Major
The metabolism of Acalabrutinib can be decreased when combined with Cyclosporine.
Alectinib
Major
The metabolism of Alectinib can be decreased when combined with Cyclosporine.
Aliskiren
Major
The serum concentration of Aliskiren can be increased when it is combined with Cyclosporine.
Aminophylline
Major
The metabolism of Aminophylline can be decreased when combined with Cyclosporine.
Gengraf Toxicity & Overdose RiskThe lowest toxic dose of cyclosporine in rats is 1480 mg/kg and the toxicity level for humans is 12 mg/kg. Symptoms of an overdose include nausea, flushing, trembling, dizziness, vomiting, and loss of appetite. These symptoms usually go away within a day, but the feeling of increased body girth may take up to two weeks to resolve. Treatment for cyclosporine overdose should include forced vomiting and stomach pumping within two hours of ingestion, as dialysis and charcoal hemoperfusion are not effective methods of removing the drug from the body.
Gengraf Novel Uses: Which Conditions Have a Clinical Trial Featuring Gengraf?
81 clinical trials are being conducted to investigate the potential of Gengraf to alleviate Chronic Graft Versus Host Disease, Kidney Diseases and Ulcerative Colitis.Condition
Clinical Trials
Trial Phases
Therapeutic immunosuppression
0 Actively Recruiting
Rheumatoid Arthritis
0 Actively Recruiting
Bone Marrow
1 Actively Recruiting
Early Phase 1
severe, recalcitrant Plaque psoriasis
0 Actively Recruiting
Nephrotic Syndrome
11 Actively Recruiting
Phase 2, Not Applicable, Phase 1, Phase 3
Disease
0 Actively Recruiting
Prophylaxis against graft versus host disease
0 Actively Recruiting
Liver
0 Actively Recruiting
Heymann Nephritis
3 Actively Recruiting
Phase 2, Phase 1
Glomerulosclerosis
0 Actively Recruiting
Prophylaxis against heart transplant rejection
0 Actively Recruiting
Organ Transplantation
0 Actively Recruiting
Excessive tearing
0 Actively Recruiting
Transplantation
0 Actively Recruiting
Lupus Nephritis
23 Actively Recruiting
Phase 3, Phase 2, Phase 1, Not Applicable
Not responsive to other therapy
0 Actively Recruiting
Kidney Transplantation
0 Actively Recruiting
Glomerulosclerosis, Focal Segmental
12 Actively Recruiting
Not Applicable, Phase 3, Early Phase 1, Phase 2, Phase 1
Uveitis
5 Actively Recruiting
Phase 4, Not Applicable, Phase 2, Phase 1, Phase 3
Nephrotic Syndrome
0 Actively Recruiting
Gengraf Reviews: What are patients saying about Gengraf?
5Patient Review
11/19/2008 I received a kidney transplant in 1999 and, overall, I think it was successful.
5Patient Review
1/22/2009 I've been using this medication for less than a year and it's doing a great job. I never had any difficulty with nausea, and my kidneys are tested regularly and doing fine so far.
5Patient Review
1/23/2008 I have been on Genfraf for 5 years and was wondering what could cause my level to drop low when I take 2 doses BID? I would like to know how long it takes gengraf to get through my system, and how long I would take it after vomiting?
5Patient Review
7/15/2009 I received a liver transplant in December 2002 and was prescribed this medication 2-3 months afterwards. I have had no side effects or rejections, and it has kept me healthy overall. The only downside is that it is quite expensive; however, the capsules are easy to take. I believe it raised my blood pressure slightly, but I take Norvasc 5mg once daily to counteract that. All of my blood work has been normal thus far while taking this drug.
3.7Patient Review
10/24/2012 After losing my insurance, I had to switch from Neoral to Gengraf. I feel like Gengraf doesn't work as well for me; I'm constantly in pain and I don't know if it's the medication or not.
2.7Patient Review
2/24/2012 I switched to Gengraf from another Cyclosporine modulator a few months ago, and I've developed mouth and throat sores. Is this a common side effect?
1Patient Review
11/30/2009 I do not take this medication, but I know someone who does. They've been taking it for at least three years, even though it's expired. I'm wondering if there are any health risks associated with taking expired medication. Can anyone provide some insight?
Patient Q&A Section about gengraf
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.What is the difference between Neoral and GENGRAF?
"Gengraf is equivalent to Neoral in terms of efficacy. Additionally, Gengraf is well tolerated and can be used interchangeably with Neoral in stable Chinese renal allograft recipients."
Answered by AI
Is GENGRAF an immunosuppressant?
"GENGRAF is a drug that suppresses the immune system, making the body more susceptible to infection and disease. When taken with other immunosuppressant drugs, the effects are amplified."
Answered by AI
Is GENGRAF brand or generic?
"Gengraf is an immunosuppressant drug used to prevent organ rejection in people who have undergone kidney, liver, or heart transplant surgery. It is also sometimes used to treat severe cases of psoriasis or rheumatoid arthritis. A generic form of Gengraf is also available."
Answered by AI
What is GENGRAF used for?
"Cyclosporine capsules and oral solution are prescription medicines used to help prevent organ rejection in people who have received a kidney, liver, or heart transplant."
Answered by AI